NASDAQ : MYGN
Myriad Genetics, Inc. — Key statistics
Healthcare · Diagnostics & Research · United States
Last price 6.67 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 637.98M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 607.38M |
| Enterprise Value | 702.68M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 95.65M |
| Shares Outstanding | 95.65M |
| Shares Change (YoY) | +2.46% |
| Shares Change (QoQ) | +1.17% |
| Owned by Insiders (%) | 4.17% |
| Owned by Institutions (%) | 83.42% |
| Float | 79.29M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.75 |
| Forward PS | 0.76 |
| PB Ratio | 2.00 |
| P/TBV Ratio | 5.16 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 78.88 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 0.87 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.21 |
| Quick Ratio | 1.72 |
| Debt / Equity | 0.69 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.52 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -32.54% |
| Return on Assets (ROA) | -8.59% |
| Return on Invested Capital (ROIC) | -21.97% |
| Return on Capital Employed (ROCE) | -17.81% |
| Weighted Average Cost of Capital (WACC) | 11.45% |
| Revenue Per Employee | $298,741 |
| Profits Per Employee | -$41,704 |
| Employee Count | 2,700 |
| Asset Turnover | 1.23 |
| Inventory Turnover | 8.48 |
Taxes
| Measure | Value |
|---|
| Income Tax | 800,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.64 |
| 52-Week Price Change | -19.72% |
| 50-Day Moving Average | 4.21 |
| 200-Day Moving Average | 4.61 |
| Relative Strength Index (RSI) | 72.65 |
| Average Volume (20 Days) | 3,148,261 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 9.27M |
| Short Previous Month | 8.55M |
| Short % of Shares Out | 9.69% |
| Short % of Float | 11.69% |
| Short Ratio (days to cover) | 4.59 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 806.60M |
| Gross Profit | 555.20M |
| Operating Income | -90.50M |
| Pretax Income | -111.80M |
| Net Income | -112.60M |
| EBITDA | -40.30M |
| EBIT | -90.50M |
| Loss Per Share | -$1.20 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 115.20M |
| Total Debt | 210.50M |
| Net Cash | -95.30M |
| Net Cash Per Share | -$1.00 |
| Equity (Book Value) | 303.90M |
| Book Value Per Share | 3.18 |
| Working Capital | 158.30M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 7.70M |
| Capital Expenditures | -15.00M |
| Depreciation & Amortization | 50.20M |
| Net Borrowing | 64.90M |
| Free Cash Flow | -7.30M |
| FCF Per Share | -$0.08 |
Margins
| Measure | Value |
|---|
| Gross Margin | 68.83% |
| Operating Margin | -11.22% |
| Pretax Margin | -13.86% |
| Profit Margin | -13.96% |
| EBITDA Margin | -5.00% |
| EBIT Margin | -11.22% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.46% |
| Shareholder Yield | -2.46% |
| Earnings Yield | -18.95% |
| FCF Yield | -1.20% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $4.49 |
| Price Target Difference | -29.34% |
| Analyst Consensus | Hold |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 2.24% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Mar 26, 2009 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -0.58 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |